{"id":1944,"date":"2023-03-16T13:36:56","date_gmt":"2023-03-16T13:36:56","guid":{"rendered":"https:\/\/founderlodge.com\/latest-news\/?p=1944"},"modified":"2023-03-16T13:36:57","modified_gmt":"2023-03-16T13:36:57","slug":"switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners","status":"publish","type":"post","link":"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/","title":{"rendered":"Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-186.png\" alt=\"\" class=\"wp-image-1945\" width=\"210\" height=\"115\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-186.png 388w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-186-300x164.png 300w\" sizes=\"(max-width: 210px) 100vw, 210px\" \/><\/figure>\n\n\n\n<p>San Francisco, California \u2013 <a href=\"https:\/\/switchthera.com\/\">Switch Therapeutics<\/a>, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases \u2013 affecting the central nervous system and systemic indications \u2013 with significant unmet needs, announced a $52 million Series A financing. The round was led by <a href=\"https:\/\/www.insightpartners.com\/\">Insight Partners<\/a> and included investments from<a href=\"http:\/\/www.dolbyventures.com\/\"> Dolby Family Ventures<\/a>, <a href=\"https:\/\/upfront.com\/\">Upfront Ventures<\/a>, <a href=\"https:\/\/boldcapitalpartners.com\/\">BOLD Capital Partners<\/a>, <a href=\"https:\/\/www.lilly.com\/\">Eli Lilly &amp; Company<\/a>, <a href=\"https:\/\/www.digitalisventures.com\/\">Digitalis Ventures<\/a>, <a href=\"https:\/\/www.freeflow.zone\/\">FreeFlow Ventures<\/a>, and <a href=\"https:\/\/www.ucbventures.com\/\">UCB Ventures<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"577\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-187-1024x577.png\" alt=\"\" class=\"wp-image-1946\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-187-1024x577.png 1024w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-187-300x169.png 300w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-187-768x433.png 768w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-187.png 1037w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Switch Therapeutics is co-founded by Dee Datta and is based in San Francisco, California. The company\u2019s mission is to develop treatments for diseases affecting the central nervous system and systemic indications with significant unmet needs. To achieve this goal, Switch has developed a novel gene knockdown approach based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard, and City of Hope called CASi (Conditionally Activated siRNAs). This proprietary platform combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell-selective RNAi activity.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"645\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-188-1024x645.png\" alt=\"\" class=\"wp-image-1947\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-188-1024x645.png 1024w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-188-300x189.png 300w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-188-768x484.png 768w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-188.png 1195w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>\u201cWe are very excited about our Series A funding as it will enable us to further advance our lead development program into clinical studies as well as expand our pipeline into additional disease areas where we can make a meaningful difference in patient outcomes.,\u201d said <a href=\"https:\/\/www.linkedin.com\/in\/deedatta\/\">Dee Datta<\/a> Co-Founder at Switch Therapeutics.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases \u2013 affecting the central nervous system and systemic indications \u2013 with significant unmet needs, announced a $52 million [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1948,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"categories":[2],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.2.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners - Founder Lodge Latest News Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners<\/title>\n<meta name=\"description\" content=\"San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases \u2013 affecting the central nervous system and systemic indications \u2013 with significant unmet needs, announced a $52 million Series A financing. The round was led by Insight Partners and included investments from Dolby Family Ventures, Upfront Ventures, BOLD Capital Partners, Eli Lilly &amp; Company, Digitalis Ventures, FreeFlow Ventures, and UCB Ventures.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners - Founder Lodge Latest News Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners\" \/>\n<meta property=\"og:description\" content=\"San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases \u2013 affecting the central nervous system and systemic indications \u2013 with significant unmet needs, announced a $52 million Series A financing. The round was led by Insight Partners and included investments from Dolby Family Ventures, Upfront Ventures, BOLD Capital Partners, Eli Lilly &amp; Company, Digitalis Ventures, FreeFlow Ventures, and UCB Ventures.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/\" \/>\n<meta property=\"og:site_name\" content=\"Founder Lodge Latest News\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-16T13:36:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-16T13:36:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-189.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1439\" \/>\n\t<meta property=\"og:image:height\" content=\"827\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"ucheezuma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ucheezuma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/\"},\"author\":{\"name\":\"ucheezuma\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3\"},\"headline\":\"Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners\",\"datePublished\":\"2023-03-16T13:36:56+00:00\",\"dateModified\":\"2023-03-16T13:36:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/\"},\"wordCount\":240,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\"},\"articleSection\":[\"Daily Startup Funding News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/\",\"name\":\"Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners - Founder Lodge Latest News Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners\",\"isPartOf\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#website\"},\"datePublished\":\"2023-03-16T13:36:56+00:00\",\"dateModified\":\"2023-03-16T13:36:57+00:00\",\"description\":\"San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases \u2013 affecting the central nervous system and systemic indications \u2013 with significant unmet needs, announced a $52 million Series A financing. The round was led by Insight Partners and included investments from Dolby Family Ventures, Upfront Ventures, BOLD Capital Partners, Eli Lilly & Company, Digitalis Ventures, FreeFlow Ventures, and UCB Ventures.\",\"breadcrumb\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/founderlodge.com\/latest-news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#website\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/\",\"name\":\"Founder Lodge Latest News\",\"description\":\"Get the latest updates on funding rounds and investment news for startups and businesses. Stay informed on capital raising trends and who&#039;s raising capital.\",\"publisher\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/founderlodge.com\/latest-news\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\",\"name\":\"Founder Lodge\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Founder Lodge\"},\"image\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3\",\"name\":\"ucheezuma\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g\",\"caption\":\"ucheezuma\"},\"url\":\"https:\/\/founderlodge.com\/latest-news\/author\/ucheezuma\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners - Founder Lodge Latest News Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners","description":"San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases \u2013 affecting the central nervous system and systemic indications \u2013 with significant unmet needs, announced a $52 million Series A financing. The round was led by Insight Partners and included investments from Dolby Family Ventures, Upfront Ventures, BOLD Capital Partners, Eli Lilly & Company, Digitalis Ventures, FreeFlow Ventures, and UCB Ventures.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/","og_locale":"en_US","og_type":"article","og_title":"Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners - Founder Lodge Latest News Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners","og_description":"San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases \u2013 affecting the central nervous system and systemic indications \u2013 with significant unmet needs, announced a $52 million Series A financing. The round was led by Insight Partners and included investments from Dolby Family Ventures, Upfront Ventures, BOLD Capital Partners, Eli Lilly & Company, Digitalis Ventures, FreeFlow Ventures, and UCB Ventures.","og_url":"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/","og_site_name":"Founder Lodge Latest News","article_published_time":"2023-03-16T13:36:56+00:00","article_modified_time":"2023-03-16T13:36:57+00:00","og_image":[{"width":1439,"height":827,"url":"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/03\/image-189.png","type":"image\/png"}],"author":"ucheezuma","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ucheezuma","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/#article","isPartOf":{"@id":"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/"},"author":{"name":"ucheezuma","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3"},"headline":"Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners","datePublished":"2023-03-16T13:36:56+00:00","dateModified":"2023-03-16T13:36:57+00:00","mainEntityOfPage":{"@id":"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/"},"wordCount":240,"commentCount":0,"publisher":{"@id":"https:\/\/founderlodge.com\/latest-news\/#organization"},"articleSection":["Daily Startup Funding News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/","url":"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/","name":"Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners - Founder Lodge Latest News Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners","isPartOf":{"@id":"https:\/\/founderlodge.com\/latest-news\/#website"},"datePublished":"2023-03-16T13:36:56+00:00","dateModified":"2023-03-16T13:36:57+00:00","description":"San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates San Francisco, California \u2013 Switch Therapeutics, an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases \u2013 affecting the central nervous system and systemic indications \u2013 with significant unmet needs, announced a $52 million Series A financing. The round was led by Insight Partners and included investments from Dolby Family Ventures, Upfront Ventures, BOLD Capital Partners, Eli Lilly & Company, Digitalis Ventures, FreeFlow Ventures, and UCB Ventures.","breadcrumb":{"@id":"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/founderlodge.com\/latest-news\/switch-therapeutics-announces-52-million-series-a-funding-round-led-by-insight-partners\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/founderlodge.com\/latest-news\/"},{"@type":"ListItem","position":2,"name":"Switch Therapeutics Announces $52 Million Series A Funding Round Led by Insight Partners"}]},{"@type":"WebSite","@id":"https:\/\/founderlodge.com\/latest-news\/#website","url":"https:\/\/founderlodge.com\/latest-news\/","name":"Founder Lodge Latest News","description":"Get the latest updates on funding rounds and investment news for startups and businesses. Stay informed on capital raising trends and who&#039;s raising capital.","publisher":{"@id":"https:\/\/founderlodge.com\/latest-news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/founderlodge.com\/latest-news\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/founderlodge.com\/latest-news\/#organization","name":"Founder Lodge","url":"https:\/\/founderlodge.com\/latest-news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Founder Lodge"},"image":{"@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3","name":"ucheezuma","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g","caption":"ucheezuma"},"url":"https:\/\/founderlodge.com\/latest-news\/author\/ucheezuma\/"}]}},"_links":{"self":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/1944"}],"collection":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/comments?post=1944"}],"version-history":[{"count":1,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/1944\/revisions"}],"predecessor-version":[{"id":1949,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/1944\/revisions\/1949"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/media\/1948"}],"wp:attachment":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/media?parent=1944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/categories?post=1944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/tags?post=1944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}